Institut Jules Bordet

Clinical activity includes early breast cancer, luminal B breast cancer, HER2-positive breast carcinoma, and triple-negative breast cancer, with attention to treatment selection, tumour profiling, and surgical planning.

• HER2 molecular imaging
• Antibody-drug conjugate sequencing
• Breast-conserving surgery margin assessment
• Neoadjuvant and perioperative strategies

Research also covers imaging-guided decision-making, intraoperative assessment, and systemic treatment approaches in both hormone receptor-positive and aggressive breast cancer subtypes.